Objective: Fast-disintegrating tablets (FDTs) have gained significant attention in pharmaceutical research due to their ability to disintegrate rapidly in the oral cavity without the need for water. This improves patient compliance, particularly in pediatric and geriatric populations. The present study formulated and evaluated FDTs using various Superdisintegrants to enhance drug dissolution and bioavailability.

Methods: The tablets were prepared by direct compression, employing sodium starch glycolate, croscarmellose sodium, and crospovidone as Superdisintegrants at different concentrations. A comprehensive preformulation study assessed the powder blend’s flow properties, including bulk density, tapped density, Carr’s index, Hausner’s ratio, and angle of repose, to ensure uniformity and ease of compression. Post-compression evaluation of the tablets involved weight variation, hardness, friability, thickness, disintegration time, and content uniformity to determine their physicochemical properties.

Results: The results revealed that all formulations exhibited satisfactory pre-compression and post-compression characteristics. However, formulation F6 (containing 15 mg of crospovidone) had the shortest disintegration time (3 min 10 s) and the highest drug release (99.56% in 30 minutes) compared to the other formulations. F6 also showed the lowest friability (0.11%), indicating excellent mechanical strength; its content uniformity was highest (99.81%), ensuring uniform drug distribution in each tablet. In vitro dissolution studies demonstrated that drug release significantly improved with increasing superdisintegrant concentration, with crospovidone being the most effective among those tested. Kinetic analysis indicated that the formulations followed zero-order release kinetics and fit the Higuchi diffusion model, suggesting a diffusion-controlled release mechanism. Based on these findings, the optimized formulation (F6) was identified as the most promising due to its rapid disintegration, enhanced dissolution rate, and superior mechanical properties.

Conclusion: This study highlights the significance of selecting an appropriate superdisintegrant to achieve optimal tablet performance. The use of crospovidone at 15 mg was the most effective in producing FDTs with excellent pharmaceutical characteristics. Formulation F6 is recommended for further in vivo evaluation and potential commercialization, offering significant advantages in improving drug bioavailability and patient compliance.